Longitudinal Brain Imaging Study of Amyloid and Tau in Typical and Atypical Alzheimers Disease

What this Trial Is About

Researchers are studying amyloid and tau protein buildup in the brains of patients with typical and atypical Alzheimers Disease, including Logopenic Aphasia LPA and Posterior Cortical Atrophy PCA. The study aims to understand how these protein levels may change over one year using advanced molecular and structural imaging techniques. This observational study is led by the Mayo Clinic and focuses on diagnostic evaluation to better understand disease progression. Participants will receive two Tau PET scans using F-18 AV 1451 and two PiB PET scans using C-11 PiB during the study. These imaging scans will help measure the amount of tau and amyloid proteins in the brain. The study does not involve treatment but focuses on detailed brain imaging at baseline and after one year to track changes in protein burden. Throughout the study, participants will undergo assessments to monitor amyloid and tau protein levels and their rates of change over time. The main outcomes include measuring amyloid and tau protein amounts and their progression over five years, with specific evaluations at baseline and one year. Participants will be monitored for safety and stability to ensure suitability for imaging procedures, with total involvement lasting up to several years as outcomes are tracked.

Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study